In the world of growth investing, strategies that systematically identify companies with strong and speeding business momentum are highly sought after. One such disciplined approach is outlined in Louis Navellier’s The Little Book That Makes You Rich, which details eight fundamental rules for selecting superior growth stocks. The methodology focuses on quantifiable metrics that signal a company is not just growing, but doing so with rising profitability, positive analyst sentiment, and operational quality. A stock screen built on these principles recently identified TransMedics Group Inc (NASDAQ:TMDX) as a candidate worthy of closer study.
A Screen for Speeding Growth
The "Little Book" strategy is made to filter for companies showing strong fundamental momentum. The eight rules stress positive earnings revisions and surprises, speeding sales and earnings growth, widening profit margins, strong cash flow creation, and a high return on equity. The aim is to find firms where business trends are getting better, often before the wider market's notice, which can lead to large stock price gains. TransMedics seems to satisfy this strict set of conditions, as shown by its recent financial performance.
How TransMedics Satisfies the Key Conditions
The provided data shows TransMedics producing outstanding results across multiple rules central to Navellier's growth investing philosophy:
- Positive Earnings Revisions & Surprises: Analyst confidence is increasing, with EPS estimates for the next quarter revised upward by 8.04% over the last three months. More notably, the company has posted a positive earnings surprise in each of the last four quarters, with an average beat of 92.06%. Steady outperformance makes analysts re-evaluate their models, a main factor for future earnings growth expectations.
- Strong and Speeding Growth: The company is showing fast expansion.
- Revenue grew 41.20% year-over-year and 32.24% quarter-over-quarter.
- Earnings growth is even more marked, with EPS rising 162.77% over the past year and a notable 450% in the most recent quarter compared to the same period last year.
- Importantly, this shows earnings momentum; the current quarterly EPS growth (450%) greatly exceeds the growth from the comparable quarter a year ago (115.39%), showing a speed increase.
- Widening Profitability and Strong Cash Flow: As sales rise, TransMedics is successfully turning them into higher profit. Its operating margin has widened by 116.05% over the past year, showing large operating leverage. Also, the company's free cash flow—a key sign of financial health and self-supporting growth—rose by 187.28%.
- High Return on Equity: The strategy looks for efficient capital users. TransMedics' Return on Equity (ROE) is at 25.84%, showing it is producing large profit from shareholder investments, a sign of a high-quality growth business.
Fundamental Health and Valuation Setting
A review of TransMedics' broader fundamental analysis report provides a balanced view. The company gets a firm overall rating, with its Growth score of 8 out of 10 being the notable point, directly supporting the "Little Book" screen's findings. Profitability metrics are strong, with industry-leading margins and returns on assets and invested capital.
The financial health picture is mixed but steady. The company keeps excellent liquidity ratios and a good Altman-Z score, suggesting low near-term bankruptcy risk. However, it holds a large debt load, shown in a high Debt-to-Equity ratio, which is typical for quickly scaling companies spending heavily in growth. From a valuation point of view, traditional metrics like P/E and Price/Forward Earnings seem costly on an absolute basis. Still, when changed for its outstanding growth rate—a method central to growth investing—the valuation seems more acceptable relative to its industry peers.
Conclusion and Next Steps
For investors using a strategy like the one in The Little Book That Makes You Rich, TransMedics offers a strong case study. It meets the necessary conditions for earnings momentum, sales speed increase, margin widening, and high returns on capital. The company's role as an innovator in organ transplant technology provides a concrete growth story supporting these solid numbers.
It is important to recall that screens are beginning points for more study. The high growth rates built into TransMedics' current valuation also mean high expectations that must be steadily met. Investors should watch the continuation of its growth path, competitive field, and balance sheet management.
This stock was found using a screen based on Louis Navellier's "Little Book" strategy. You can examine the current screen settings and see other possible candidates by visiting the ChartMill trading ideas library.
Disclaimer: This article is for informational purposes only and does not constitute financial advice, a recommendation, or an offer to buy or sell any securities. The analysis is based on data believed to be reliable, but its accuracy cannot be guaranteed. Investing involves risk, including the potential loss of principal. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.